Table 2.
Infliximab group | Ciclosporin group | |
---|---|---|
Pre-baseline | 16/135 (12%) | 26/135 (19%) |
3 months | 56/131 (43%) | 66/134 (49%) |
6 months | 56/131 (43%) | 57/131 (44%) |
12 months | 39/126 (31%) | 45/124 (36%) |
18 months | 23/96 (24%) | 19/95 (20%) |
24 months | 18/61 (30%) | 20/66 (30%) |
30 months | 10/36 (28%) | 9/39 (23%) |
36 months | 4/17 (24%) | 3/17 (18%) |
Data are n/N (%).